EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

Guidelines Metastatic prostate cancer Prostate cancer Relapsing prostate cancer

Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
29 Apr 2024
Historique:
received: 02 03 2024
revised: 14 03 2024
accepted: 03 04 2024
medline: 1 5 2024
pubmed: 1 5 2024
entrez: 30 4 2024
Statut: aheadofprint

Résumé

The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (PCa) have been updated. Here we provide a summary of the 2024 guidelines. The panel performed a literature review of new data, covering the time frame between 2020 and 2023. The guidelines were updated and a strength rating for each recommendation was added on the basis of a systematic review of the evidence. Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. New treatment options, such as androgen receptor-targeted agents (ARTAs), ARTA + chemotherapy combinations, PARP inhibitors and their combinations, and prostate-specific membrane antigen-based therapy have become available for men with metastatic PCa. Evidence for relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These guidelines reflect the multidisciplinary nature of PCa management. The full version is available online (http://uroweb.org/guideline/ prostate-cancer/). This article summarises the 2024 guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are based on evidence and guide doctors in discussing treatment decisions with their patients. The guidelines are updated every year.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (PCa) have been updated. Here we provide a summary of the 2024 guidelines.
METHODS METHODS
The panel performed a literature review of new data, covering the time frame between 2020 and 2023. The guidelines were updated and a strength rating for each recommendation was added on the basis of a systematic review of the evidence.
KEY FINDINGS AND LIMITATIONS UNASSIGNED
Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. New treatment options, such as androgen receptor-targeted agents (ARTAs), ARTA + chemotherapy combinations, PARP inhibitors and their combinations, and prostate-specific membrane antigen-based therapy have become available for men with metastatic PCa.
CONCLUSIONS AND CLINICAL IMPLICATIONS CONCLUSIONS
Evidence for relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These guidelines reflect the multidisciplinary nature of PCa management. The full version is available online (http://uroweb.org/guideline/ prostate-cancer/).
PATIENT SUMMARY RESULTS
This article summarises the 2024 guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are based on evidence and guide doctors in discussing treatment decisions with their patients. The guidelines are updated every year.

Identifiants

DOI: 10.1016/j.eururo.2024.04.010 PMID: 38688773
pubmed: 38688773
pii: S0302-2838(24)02306-6
doi: 10.1016/j.eururo.2024.04.010
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Auteurs

Derya Tilki (D)

Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey. Electronic address: d.tilki@uke.de.

Roderick C N van den Bergh (RCN)

Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Erik Briers (E)

Patient advocate, Hasselt, Belgium.

Thomas Van den Broeck (T)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Oliver Brunckhorst (O)

Department of Urology, King's College London, London, UK.

Julie Darraugh (J)

European Association of Urology, Arnhem, The Netherlands.

Daniel Eberli (D)

Department of Urology, University Hospital Zurich, Zurich, Switzerland.

Gert De Meerleer (G)

Department of Radiation Oncology, University Hospital Leuven, Leuven, Belgium.

Maria De Santis (M)

Department of Urology, Universitätsmedizin Berlin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.

Andrea Farolfi (A)

Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Giorgio Gandaglia (G)

Division of Oncology/Unit of Urology, Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Silke Gillessen (S)

Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

Nikolaos Grivas (N)

Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Ann M Henry (AM)

Leeds Cancer Centre, St. James's University Hospital and University of Leeds, Leeds, UK.

Michael Lardas (M)

Department of Urology, Metropolitan General Hospital, Athens, Greece.

Geert J L H van Leenders (G)

Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Matthew Liew (M)

Department of Urology, Liverpool University Hospitals NHS Trust, Liverpool, UK.

Estefania Linares Espinos (E)

Department of Urology, University Hospital La Paz, Madrid, Spain.

Jan Oldenburg (J)

Akershus University Hospital, Lørenskog, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.

Inge M van Oort (IM)

Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.

Daniela E Oprea-Lager (DE)

Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, VU Medical Center, Amsterdam, The Netherlands.

Guillaume Ploussard (G)

Department of Urology, La Croix du Sud Hospital, Toulouse, France.

Matthew J Roberts (MJ)

Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Australia; Faculty of Medicine, The University of Queensland Centre for Clinical Research, Herston, Australia.

Olivier Rouvière (O)

Department of Imaging, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Université de Lyon, Université Lyon 1, UFR Lyon-Est, Lyon, France.

Ivo G Schoots (IG)

Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Natasha Schouten (N)

European Association of Urology, Arnhem, The Netherlands.

Emma J Smith (EJ)

European Association of Urology, Arnhem, The Netherlands.

Johan Stranne (J)

Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Urology, Sahlgrenska University Hospital-Västra Götaland, Gothenburg, Sweden.

Thomas Wiegel (T)

Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany.

Peter-Paul M Willemse (PM)

Department of Urology, Cancer Center University Medical Center Utrecht, Utrecht, The Netherlands.

Philip Cornford (P)

Department of Urology, Liverpool University Hospitals NHS Trust, Liverpool, UK.

Classifications MeSH